Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus FLUOXYMESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus FLUOXYMESTERONE.
DANAZOL vs FLUOXYMESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
300-600 mg orally twice daily; maximum 800 mg/day
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
None Documented
None Documented
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Category C
Category C
Androgen/Antigonadotropin
Androgen
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."